Best IPF Drug Combinations in 2026: What AI Research Reveals

Idiopathic pulmonary fibrosis treatment has historically relied on single-drug therapy. Nintedanib and pirfenidone, both approved in 2014, remain the standard of care. In October 2025, the FDA approved nerandomilast (formerly BI 1015550), the first new IPF drug in over a decade. But the question that drives modern research is whether combinations of drugs can outperform any single agent.

Why Drug Combinations Matter

IPF involves multiple biological pathways simultaneously. TGF-beta drives fibroblast activation. Senescent cells accumulate and secrete inflammatory factors. The extracellular matrix stiffens, creating a feedback loop that accelerates disease. No single drug targets all of these mechanisms.

The rationale for combination therapy is straightforward: attack multiple pathways at the same time. This approach has proven effective in oncology, HIV treatment, and tuberculosis. In IPF, clinical evidence for combinations is still emerging, but computational modeling provides strong theoretical support.

Standard Monotherapy Results

In clinical trials, nintedanib reduces FVC decline by approximately 50% compared to placebo. Pirfenidone achieves a similar reduction. Nerandomilast, in the FIBRONEER-IPF trial, showed a reduction in FVC decline of approximately 63% at 52 weeks. These are meaningful results, but none of these drugs stop progression entirely, and none reverse existing fibrosis.

Top Combinations from the PF-Atlas Solver

The PF-Atlas genetic algorithm has tested over 2 million drug combinations against a biological model of lung fibrosis. Each combination is scored on FVC improvement, toxicity, pill burden, drug-drug interactions, and cost. The top results fall into three categories.

Best 2-Drug Combination

Nintedanib + nerandomilast emerges as the strongest dual therapy. In simulation, this combination slows FVC decline by approximately 75% compared to no treatment. The two drugs have complementary mechanisms: nintedanib inhibits tyrosine kinases (FGFR, PDGFR, VEGFR) while nerandomilast inhibits PDE4B, reducing inflammation and TGF-beta signaling. Side effect overlap is minimal.

Best 3-Drug Combination

Adding pamrevlumab (anti-CTGF antibody) to the nintedanib + nerandomilast pair produces the top 3-drug result. Pamrevlumab targets connective tissue growth factor, a downstream mediator of TGF-beta that directly promotes collagen production. The Phase 3 ZEPHYRUS trials for pamrevlumab were discontinued in 2023 due to insufficient efficacy as monotherapy, but the PF-Atlas solver suggests it may be more effective as part of a combination.

The 7-Drug Regenerative Protocol

The most ambitious result from the solver is a 7-drug sequential protocol that achieves FVC improvement from 50% to 69.5% in 52-week simulation. This suggests not merely slowing disease but partially reversing it. The protocol uses:

1. Nintedanib (anti-fibrotic baseline)
2. Pirfenidone (anti-inflammatory + anti-fibrotic)
3. Nerandomilast (PDE4B inhibition)
4. Pamrevlumab (anti-CTGF)
5. PRM-151 / pentraxin-2 (macrophage modulation, ECM repair)
6. Saracatinib (Src kinase inhibition, anti-fibrotic)
7. GLPG1690 / ziritaxestat (autotaxin inhibition, LPA pathway)

The drugs are introduced sequentially over 6 phases, not all at once. This reduces toxicity risk and allows dose titration. The protocol details, including dosing schedules and monitoring targets, are available in the Treatment Sequencer panel of PF-Atlas.

Nintedanib + Pirfenidone: The Existing Evidence

The INJOURNEY trial (2018) studied nintedanib + pirfenidone and found the combination was tolerable, with GI side effects being the primary concern. The study was not powered for efficacy, but PF-Atlas modeling suggests a modest benefit over either drug alone. For patients already stable on one drug, adding the second may provide incremental improvement.

Limitations

All combination results from PF-Atlas are computational. The biological model, while detailed, is a simplification of real human physiology. Clinical validation is essential before any combination protocol is used in practice. Patients should not alter their treatment without consulting their physician.

The PF-Atlas solver results are designed to guide research priorities and help physicians understand which combinations have the strongest theoretical basis. They are not medical advice.

Nintedanib vs Pirfenidone: A Complete Comparison for IPF Patients

Nintedanib (brand name Ofev) and pirfenidone (brand name Esbriet) are the two most widely prescribed drugs for idiopathic pulmonary fibrosis. Both were approved in 2014 and both slow disease progression. But they work differently, have different side effects, and may suit different patient profiles. This article provides a detailed comparison to help patients and physicians make informed decisions.

Mechanism of Action

Nintedanib is a triple tyrosine kinase inhibitor. It blocks FGFR (fibroblast growth factor receptor), PDGFR (platelet-derived growth factor receptor), and VEGFR (vascular endothelial growth factor receptor). By inhibiting these signaling pathways, nintedanib reduces fibroblast proliferation, migration, and transformation into myofibroblasts.

Pirfenidone has a less clearly defined mechanism. It reduces TGF-beta expression, inhibits collagen synthesis, and has anti-inflammatory and antioxidant properties. It appears to work through multiple pathways rather than a single molecular target.

Efficacy

Both drugs reduce the rate of FVC decline by approximately 50% compared to placebo. The INPULSIS trials (nintedanib) and ASCEND trial (pirfenidone) demonstrated this effect over 52 weeks. Neither drug stops FVC decline completely, and neither reverses existing fibrosis.

Head-to-head comparison data is limited. No large randomized trial has directly compared the two drugs. Retrospective analyses and real-world studies suggest comparable efficacy, though some observational data indicates pirfenidone may have a slight mortality benefit. The evidence is not conclusive.

Side Effects

Nintedanib causes diarrhea in approximately 62% of patients. This is the most common side effect and is typically manageable with loperamide and dose reduction. Liver enzyme elevation occurs in approximately 14% of patients. Nausea and decreased appetite are also reported.

Pirfenidone causes nausea in approximately 36% of patients, rash in 30%, and photosensitivity (increased sensitivity to sunlight) in 12%. Patients on pirfenidone should use sunscreen and avoid prolonged sun exposure. GI symptoms tend to be milder than with nintedanib, but the photosensitivity is a unique concern.

Cost

Both drugs are expensive. In the United States, the list price for nintedanib is approximately $8,000 to $10,000 per month. Pirfenidone costs approximately $8,000 to $9,000 per month. Insurance coverage, co-pay assistance programs, and generic availability (pirfenidone went generic in some markets) significantly affect out-of-pocket cost.

PF-Atlas provides a Drug Access Guide with country-specific pricing, patient assistance programs, and insurance appeal letter templates.

Which Drug Is Better for Different Patients

For patients with pre-existing GI issues (irritable bowel syndrome, frequent diarrhea), pirfenidone may be better tolerated despite its own GI side effects. For patients with sun-sensitive skin or outdoor occupations, nintedanib avoids the photosensitivity risk. For patients who prefer a simpler dosing schedule, nintedanib requires only 2 pills per day versus 9 for pirfenidone.

For patients with liver disease, pirfenidone may be preferred as nintedanib carries a higher risk of liver enzyme elevation. For patients on anticoagulants, nintedanib requires monitoring due to its anti-VEGFR activity and potential bleeding risk.

In practice, the choice often depends on individual tolerability. Many patients try one drug first and switch to the other if side effects are intolerable. The INJOURNEY trial demonstrated that adding pirfenidone to nintedanib is feasible, though GI side effects increase.

The Emerging Alternative: Nerandomilast

Nerandomilast (BI 1015550), approved by the FDA in October 2025, offers a third option. It inhibits PDE4B, a phosphodiesterase involved in inflammation and TGF-beta signaling. The FIBRONEER-IPF trial showed approximately 63% reduction in FVC decline, numerically superior to both nintedanib and pirfenidone. GI tolerability data is still being collected. PF-Atlas models nerandomilast alongside 18 other drugs in its combination solver.

Open IPF Clinical Trials in 2026: A Complete Guide

Clinical trials are the primary pathway for new IPF treatments to reach patients. As of mid-2026, over 140 clinical trials related to idiopathic pulmonary fibrosis are tracked by PF-Atlas. This guide covers the most promising active trials, how to find trials that match a specific patient profile, and what to expect when participating.

Most Promising Active Trials

Several trials stand out in 2026 based on mechanism novelty, early-phase results, and the strength of the sponsoring institution.

BI 1015550 (Nerandomilast) Extension Studies

Following the FDA approval in October 2025, extension studies are evaluating long-term safety and efficacy of nerandomilast. These trials are relevant for patients already on nintedanib or pirfenidone who want to switch or add nerandomilast to their regimen.

Inhaled Therapies

Several companies are developing inhaled anti-fibrotic agents that deliver drug directly to the lungs, potentially reducing systemic side effects. These include inhaled pirfenidone formulations and novel small molecules targeting alveolar epithelial repair. Inhaled delivery could be a significant improvement over oral dosing for patients who struggle with GI side effects.

Cell Therapy and Regenerative Approaches

Early-phase trials are testing mesenchymal stem cell (MSC) infusions, AEC2 cell transplantation, and exosome-based therapies. These approaches aim not just to slow fibrosis but to actively repair damaged lung tissue. Most are in Phase 1 or Phase 2, meaning they are years from potential approval, but the biological rationale is strong.

Combination Trials

An increasing number of trials are testing drug combinations rather than single agents. These include nintedanib + nerandomilast, pirfenidone + anti-CTGF agents, and triple combinations. PF-Atlas provides mechanism-tagged listings of all combination trials.

Senolytic Therapies

Senolytics selectively clear senescent cells, which accumulate in fibrotic lungs and drive inflammation. Dasatinib + quercetin and fisetin are being tested in early-phase IPF trials. PF-Atlas models senescence clearance as one of its 12 cell-type parameters.

How to Find Trials Matching Your Profile

Most clinical trials have specific eligibility criteria based on age, FVC level, current medications, disease duration, and comorbidities. Finding a matching trial manually on ClinicalTrials.gov can be time-consuming.

PF-Atlas includes a Trial Matcher feature. After entering basic medical data (age, current FVC, current medications, country), the system filters the 140+ tracked trials to show only those for which the patient is likely eligible. Results include direct links to the trial registration page and sponsoring institution contact information.

What to Expect in a Clinical Trial

IPF clinical trials typically last 52 to 104 weeks. Participants receive either the experimental drug or a placebo (in blinded trials). All participants continue to receive standard-of-care treatment (nintedanib or pirfenidone) unless the trial protocol requires a washout period.

Typical monitoring includes pulmonary function tests (FVC, DLCO) every 4 to 8 weeks, blood tests for liver and kidney function, 6-minute walk tests, and quality-of-life questionnaires. Travel to the study site is usually required, though some trials now offer remote monitoring options.

Participation in a clinical trial does not guarantee access to the experimental drug. In randomized controlled trials, approximately half of participants receive placebo. However, many trials offer open-label extension phases where all participants receive the active drug after the blinded phase ends.

Risks and Benefits

Benefits of trial participation include access to experimental drugs that may be more effective than current options, close monitoring by specialized pulmonologists, and contribution to research that benefits future patients. Risks include potential side effects from untested drugs, the possibility of receiving placebo, and the time commitment involved.

All clinical trials must be approved by an institutional review board (IRB) and follow strict safety protocols. Participants can withdraw at any time for any reason.

Finding Trials by Country

PF-Atlas tracks trial sites across 40+ countries. Major IPF research centers are concentrated in the United States, United Kingdom, Germany, Japan, Australia, and Israel. The Trial Matcher filters by country and shows distance to the nearest trial site when location data is available.

Understanding FVC in Pulmonary Fibrosis: What Your Numbers Mean

Forced Vital Capacity (FVC) is the single most important measurement in idiopathic pulmonary fibrosis. It determines disease staging, treatment decisions, transplant eligibility, and prognosis. Understanding what FVC measures, what the numbers mean, and how fast they typically change is essential for every IPF patient.

What FVC Measures

FVC measures the total volume of air a person can forcibly exhale after taking the deepest possible breath. The test is performed using a spirometer. The patient breathes in fully, then blows out as hard and as long as possible into the device. The result is reported in liters (absolute FVC) and as a percentage of the predicted value for a person of the same age, sex, and height (FVC % predicted).

In IPF, the scarring (fibrosis) of lung tissue makes the lungs stiff and less able to expand. This reduces the total volume of air the lungs can hold. As fibrosis progresses, FVC declines.

Normal FVC Ranges

A healthy adult typically has an FVC of 3 to 5 liters, depending on age, sex, and height. When expressed as a percentage of predicted, a normal FVC is 80% or higher. Values between 70% and 80% are mildly reduced. Below 50% indicates severe restriction.

How Fast FVC Typically Declines

Without treatment, FVC in IPF patients declines by approximately 150 to 250 mL per year. This translates to roughly 5% to 10% of predicted value per year, though the rate varies significantly between patients.

With nintedanib or pirfenidone, the decline is slowed to approximately 75 to 125 mL per year. With nerandomilast, early data suggests the decline may be slowed further.

The rate of decline is not constant. Some patients experience periods of relative stability followed by sudden drops. An acute exacerbation (a rapid, severe worsening) can cause FVC to drop by 10% or more in a matter of weeks.

What a 10% Decline Means

A decline of 10% or more in FVC over 6 to 12 months is considered clinically significant. It is associated with a 2 to 3 fold increase in mortality risk over the following year. This threshold is used in clinical trials as a primary endpoint and in clinical practice as a trigger for treatment changes or transplant referral.

Even a 5% decline over 6 months carries prognostic significance and may warrant a discussion with the treating physician about adjusting therapy.

FVC vs DLCO

DLCO (diffusing capacity of the lungs for carbon monoxide) is another important lung function measurement in IPF. While FVC measures air volume, DLCO measures how efficiently gases transfer from the lungs into the bloodstream. In IPF, DLCO often declines before FVC, making it an earlier marker of disease progression.

However, FVC remains the primary endpoint in clinical trials and the most widely used metric for tracking disease because it is more reproducible and less affected by technical factors.

How to Track FVC Over Time

Most IPF patients undergo pulmonary function testing every 3 to 6 months. Tracking FVC trends over time is more informative than any single measurement. A single low reading may reflect a bad day, a respiratory infection, or poor test technique. The trend over 3 or more measurements reveals the true trajectory.

PF-Atlas includes an FVC Tracker that allows patients to enter their spirometry results over time and see the trend plotted against population-level decline rates. The tracker also projects future FVC based on the observed rate of decline and compares the trajectory with and without various treatments.

When to Act on FVC Changes

Contact a pulmonologist promptly if FVC drops by 5% or more between two consecutive measurements, if breathlessness worsens suddenly, or if new symptoms (fever, rapid breathing, new cough) develop. These may indicate an acute exacerbation requiring immediate treatment.

The Emergency Protocol section of PF-Atlas provides step-by-step guidance for acute exacerbation response.

Can Pulmonary Fibrosis Be Reversed? What 2026 Research Shows

The central question in pulmonary fibrosis research is whether the damage can be undone. Current approved drugs slow progression but do not reverse fibrosis. The scarring that has already formed remains. For patients with moderate to severe disease, slowing progression is valuable but insufficient. The goal is regeneration.

As of 2026, several lines of research suggest that partial reversal of lung fibrosis may eventually be possible. None of these approaches are ready for clinical use, but the scientific foundation is growing stronger each year.

Evidence from Other Organs

Liver fibrosis, once considered irreversible, can be reversed in many patients when the underlying cause is removed. Patients with hepatitis C who achieve viral cure through direct-acting antivirals show measurable regression of liver fibrosis over 1 to 3 years. Even cirrhosis can partially reverse.

This precedent is important because it demonstrates that mammalian tissue fibrosis is not necessarily permanent. The question is whether the same principles apply to the lungs, which have a different cellular architecture and regenerative capacity than the liver.

Cross-Species Regeneration

Axolotls regenerate entire limbs, including bone, muscle, nerve, and skin. Zebrafish regenerate heart tissue after injury. African spiny mice (Acomys) regenerate skin without scarring. These species achieve regeneration through a combination of immune modulation, cell reprogramming, and controlled extracellular matrix remodeling.

Researchers are identifying the specific molecular signals that enable regeneration in these species and testing whether activating those signals in mammalian lung tissue can promote repair.

Cell Reprogramming: The OSK Approach

Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc) can reprogram adult cells back to a stem-cell-like state. Partial reprogramming, using only OSK (Oct4, Sox2, Klf4) without c-Myc, can rejuvenate cells without fully dedifferentiating them. This approach has reversed age-related changes in mouse tissues including the eye, brain, and muscle.

In the context of IPF, partial reprogramming of fibroblasts and alveolar epithelial cells could theoretically restore normal cell function without the cancer risk associated with full reprogramming. Several research groups are testing OSK delivery to lung tissue via adeno-associated virus (AAV) vectors. Results in mouse models of bleomycin-induced fibrosis show reduced collagen deposition and improved lung function, but human translation is still in preclinical stages.

TERT Gene Therapy

Telomerase reverse transcriptase (TERT) maintains telomere length, the protective caps on chromosomes that shorten with each cell division. Short telomeres are a major risk factor for IPF. Approximately 30% of familial IPF cases and 10% of sporadic cases have identifiable telomere-related mutations.

Gene therapy to deliver functional TERT to alveolar epithelial cells could restore their proliferative capacity, allowing them to replace damaged tissue. In mouse models, AAV-delivered TERT has shown improvements in lung compliance and reduction in fibrosis markers. Human clinical trials are in planning stages at several institutions.

WNT and RSPO3 Signaling

The WNT signaling pathway plays a complex role in IPF. While aberrant WNT activation contributes to fibrosis, controlled WNT signaling through RSPO3 (R-spondin 3) promotes alveolar epithelial regeneration. Recent studies show that RSPO3 administration in mouse models increases AEC2 proliferation and improves lung architecture.

The challenge is precision: activating WNT enough to promote regeneration without exacerbating fibrosis. Researchers are developing tissue-targeted delivery systems that activate RSPO3 signaling specifically in alveolar epithelial stem cells.

Senolytic Clearance as a Precondition

Senescent cells accumulate in fibrotic lungs and secrete a mix of inflammatory cytokines, proteases, and growth factors known as the senescence-associated secretory phenotype (SASP). This environment actively suppresses regeneration. Clearing senescent cells with senolytics (dasatinib + quercetin, fisetin, navitoclax) may be a necessary first step before regenerative therapies can work.

PF-Atlas models senescence as one of its 12 cell types and includes senolytic drugs in the genetic algorithm. The solver consistently identifies senolytic clearance in early treatment phases as a prerequisite for maximum FVC improvement.

The PF-Atlas 6-Phase Sequential Protocol

The PF-Atlas genetic algorithm has converged on a 6-phase sequential approach to regeneration:

1. Phase 1 (Weeks 1-4): Anti-fibrotic stabilization with nintedanib + pirfenidone. Stop the bleeding.
2. Phase 2 (Weeks 5-12): Senolytic clearance. Remove senescent cells to prepare the tissue environment.
3. Phase 3 (Weeks 13-20): Immune modulation. Shift macrophage polarization from M1 (pro-inflammatory) to M2 (pro-repair).
4. Phase 4 (Weeks 21-32): ECM softening. Reduce extracellular matrix stiffness to allow cell migration and tissue remodeling.
5. Phase 5 (Weeks 33-44): Regenerative signaling. Activate AEC2 stem cell proliferation via RSPO3/WNT modulation.
6. Phase 6 (Weeks 45-52): Consolidation. Low-dose maintenance therapy to prevent relapse.

This protocol is entirely computational. No human has received this sequence. But the model predicts FVC improvement from 50% to 69.5%, a result that, if validated clinically, would represent the first demonstration of meaningful lung fibrosis reversal.

Timeline for Clinical Availability

Senolytic therapies for IPF are in Phase 1/2 trials and could reach approval in 3 to 5 years. Cell reprogramming and TERT gene therapy are in preclinical stages, with estimated timelines of 5 to 10 years for clinical availability. Combination protocols that integrate multiple regenerative strategies are further out, likely 7 to 12 years from clinical use.

For patients today, the practical recommendation remains: start anti-fibrotic therapy early, monitor FVC closely, consider clinical trial participation, and stay informed about emerging research. PF-Atlas exists to make that last part easier.